Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line metastatic colorectal cancer patients unfit for intensive therapy
NL-OMON52901Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing Trifluridine/tipiracil + bevacizumab with Capecitabine + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Apr 2019; status: active, not recruiting.
02
Drugs
trifluridine + tipiracilbevacizumabcapecitabine
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON52901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52901.